Analysts expect that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will announce $1.28 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Alexion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.53 and the lowest estimate coming in at $1.11. Alexion Pharmaceuticals reported earnings of $1.26 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.6%. The firm is expected to announce its next earnings report on Thursday, February 15th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year earnings of $5.67 per share for the current year, with EPS estimates ranging from $5.50 to $5.90. For the next financial year, analysts anticipate that the business will report earnings of $7.11 per share, with EPS estimates ranging from $6.49 to $8.64. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter in the previous year, the business earned $1.23 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis.

Several analysts recently commented on the company. Leerink Swann reaffirmed a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 price objective (down previously from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada lifted their price objective on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $154.00.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at $122.71 on Friday. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a market capitalization of $27,410.00, a price-to-earnings ratio of 54.78, a P/E/G ratio of 1.03 and a beta of 1.17.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the sale, the chief executive officer now owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.35% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC bought a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $147,000. Dupont Capital Management Corp bought a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $156,000. BT Investment Management Ltd bought a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $165,000. YorkBridge Wealth Partners LLC boosted its stake in shares of Alexion Pharmaceuticals by 221.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock worth $173,000 after acquiring an additional 982 shares during the period. Finally, Beacon Investment Advisory Services Inc. bought a new position in shares of Alexion Pharmaceuticals in the third quarter worth about $201,000. 94.26% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Analysts Expect Alexion Pharmaceuticals, Inc. (ALXN) Will Post Earnings of $1.28 Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/14/analysts-expect-alexion-pharmaceuticals-inc-alxn-will-post-earnings-of-1-28-per-share.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.